These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The prospective study of the clinical features and outcome of HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis].
    Author: Ma H, Guo F, Wei L, Sun Y, Wang H.
    Journal: Zhonghua Yi Xue Za Zhi; 2007 Jul 10; 87(26):1832-5. PubMed ID: 17922993.
    Abstract:
    OBJECTIVE: Comparing clinical features and prognosis between HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis. METHODS: 217 chronic type B hepatitis with cirrhosis patients were prospectively studied for 35 months (3 - 47 months). Comparing clinical features and prognosis between HBeAg-negative and HBeAg-positive cirrhosis in patients with chronic type B hepatitis. RESULTS: The numbers of HBeAg-negative cirrhosis in patients with chronic type B hepatitis were more than HBeAg-positive cirrhosis; The median ALT and AST levels of HBeAg-negative patients were lower than HBeAg-positive patients; The median WBC, HGB and PLT levels of HBeAg-negative patients were lower than HBeAg-positive patients; HBV DNA positive rate and proportion of HBV DNA > 10(5) copies/ml of HBeAg-negative patients was lower than HBeAg-positive patients; The mortality rate of HBeAg-negative patients was higher than HBeAg-positive patients; among HBeAg-negative patients group, the presence rate of ascite, portal hypertensive gastrointestinal bleeding and HCC of patients treated with lamivudine were lower than the other patients, the proportion of non-presence of complications patients treated with lamivudine were higher than the other patients, the proportion of presence of one-two complications patients treated with lamivudine were lower than the other patients; among HBeAg-positive patients group, the presence rate of ascite of patients treated with lamivudine were lower than the other patients, the proportion of non-presence of complications patients treated with lamivudine were higher than the other patients. CONCLUSION: Among the liver cirrhosis patients, the numbers of HBeAg-negative cirrhosis were more than HBeAg-positive cirrhosis; HBeAg-negative patients with cirrhosis have lower liver inflammation activity; HBeAg-negative patients with cirrhosis have lower WBC, HGB and PLT levels; HBV DNA positive rate and proportion of HBV DNA > 10(5) copies/ml of HBeAg-negative patients was lower than HBeAg-positive patients; The mortality rate of HBeAg-negative patients was higher than HBeAg-positive patients; Lamivudine treatment is beneficial in HBeAg-negative and HBeAg-positive cirrhosis patients.
    [Abstract] [Full Text] [Related] [New Search]